Focus V (anlotinib) / Advenchen, Sino Biopharm - LARVOL DELTA

Updated Results of the ALTER-PA-001 Trial: A Multicenter, Open-Label, Randomized Phase II Study of Anlotinib Plus Benmelstobart in Combination with AG Versus AG Alone as First-Line Treatment for Metastatic Pancreatic Cancer (ESMO 2026) - No abstract available

Clinical • Combination therapy • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

Serplulimab Plus Anlotinib and S-1 in Second-Line or Later-Line Advanced Esophageal Squamous Cell Carcinoma (ESCC): A Phase II Study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Updated Efficacy and Safety Data of First-Line Anlotinib + Carboplatin/Paclitaxel Induction Followed by Anlotinib Maintenance in Advanced Ovarian Cancer: Phase II Multicenter Trial (ALTER-GO-010) (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Ovarian Cancer • Solid Tumor

Newly Adult Malignant Brainstem Glioma Treated with Anlotinib Plus Radiotherapy: A Multicenter, Phase II Study (ASTRO 2026) - P2 | "Anlotinib combined with radiotherapy is efficacious and well-tolerated, which might be a treatment option for newly diagnosed malignant brain stem glioma in adults."

Clinical • P2 data • Brain Cancer • Glioma • High Grade Glioma • Oncology • Solid Tumor

Neoadjuvant Sintilimab Combined with Anlotinib and Gemcitabine for High-risk Recurrent, Borderline Resectable ICC: a Prospective, Single-arm, Phase II Clinical Trial (ESMO 2026) - No abstract available

Clinical • P2 data • Oncology

Irinotecan Liposome Plus Anlotinib as Second-Line Therapy for Relapsed SCLC: Mature Progression-Free Survival and Promising Overall Survival from a Phase Ⅱ Trial (ESMO 2026) - No abstract available

Clinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Preoperative Radiotherapy with Anlotinib or Apatinib and Disease-Free Survival for Locally Advanced Soft Tissue Sarcoma: Results of Prospective Phase II Clinical Trials (ASTRO 2026) - "Preoperative RT with or without TKI/PARPi enabled good survivals in most LA-STSs with similar MWC rates. Adding TKIs improved DFS, particularly in non-WDLS subtypes. Randomized trials are needed for confirmation."

Clinical • Metastases • P2 data • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Updated Results of a single-arm, multi-center study of anlotinib combined with toripalimab in first-line treatment of unresectable or metastatic undifferentiated pleomorphic Sarcoma (ESMO 2026) - No abstract available

Clinical • Metastases • Oncology • Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma

Chidamide Combined with Anlotinib in Patients with Advanced Soft Tissue Sarcoma After Failure of Standard Therapy: A Single-Center, Single-Arm Phase II Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Cadonilimab plus Anlotinib in Patients with Advanced Soft Tissue Sarcoma After Failure of Standard First-Line Therapy: A Prospective Phase II Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

TQB2868 Plus Nab-Paclitaxel/Gemcitabine ± Anlotinib as First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: A Prospective Multicenter Two-Cohort Phase II Study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Ductal Adenocarcinoma

Integrated nal-IRI/5-FU/LV, benmelstobart, and anlotinib with or without SBRT for second-line metastatic pancreatic cancer: A phase II dual-cohort study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

Integrated Penpulimab, Anlotinib and AG Chemotherapy as First-Line Regimen for Metastatic Pancreatic Cancer: A Multi-Centered, Randomized Controlled Trial (RCT-PAAG) (ESMO 2026) - No abstract available

Clinical • Metastases • Oncology • Pancreatic Cancer • Solid Tumor

A Chemotherapy-free Adjuvant Strategy with Anlotinib Plus Benmelstobart for Resected ESCC: Phase II Results from the ALTER-E005 Study (ESMO 2026) - No abstract available

Clinical • P2 data • Esophageal Squamous Cell Carcinoma • Oncology

Chemo-radiotherapy-free neoadjuvant penpulimab plus anlotinib in frail patients with locally advanced ESCC: updated phase II results and spatial CD4⁺IDO1⁺ immunosuppressive niches associated with resistance (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Esophageal Squamous Cell Carcinoma • Oncology • CD4 • IDO1

Updated efficacy and early on-treatment ctDNA dynamics of firmonertinib plus anlotinib as first-line treatment for advanced EGFR L858R-mutant NSCLC: A phase II trial (ESMO 2026) - No abstract available

Circulating tumor DNA • Clinical • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

NEO-PIONEER: Interim Analysis of Perioperative Hypofractionated Radiotherapy Followed by Sequential Tislelizumab Plus Anlotinib in Resectable Stage II–IIIA NSCLC (ESMO 2026) - No abstract available

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Adebrelimab combined with Anlotinib and Chemotherapy Neoadjuvant Therapy Resectable Stage II-III Non-Small Cell Lung Cancer (ESMO 2026) - No abstract available

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Toripalimab Plus Interferon-α1b and Anlotinib in Unresectable Advanced Melanoma: Interim Results of a Phase II Study (ESMO 2026) - No abstract available

Metastases • P2 data • Melanoma • Oncology • Solid Tumor

Efficacy and Safety of Anlotinib-Based Therapy in Advanced Breast Cancer: A Real-World Study (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor

Impact of Anlotinib Addition to Transarterial Chemoembolization on Survival and Tumor Response in Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis (ACG 2026) - "Combination therapy significantly improved PFS (HR = 0.52; 95% CI: 0.38â0.72; p < 0.0001; I² = 0%) (Figure 1). Median OS was 17.6 vs. 9.4 months in one study, with 1-year survival rates of 66.7% vs."

Retrospective data • Review • Hepatocellular Cancer • Hypertension • Oncology • Solid Tumor

Efficacy and safety of first-line immunotherapy in advanced renal cell carcinoma: a systematic review and network meta-analysis. (PubMed, Transl Androl Urol) - "Notably, benmelstobart plus anlotinib achieved the highest ORR [odds ratio (OR): 7.55, 95% CI: 3.99-14.28], followed by pembrolizumab plus lenvatinib (OR: 4.18, 95% CI: 2.29-7.61). Other ICI plus tyrosine kinase inhibitor (TKI) combinations and nivolumab plus ipilimumab also significantly improved OS compared to sunitinib...However, these global rankings from pooled cohorts should not be interpreted as absolute clinical recommendations for all subgroups. Real-world treatment selection must be highly individualized and strictly tailored to the patient's specific International Metastatic RCC Database Consortium (IMDC) risk profile alongside the efficacy-safety trade-off."

Journal • Retrospective data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • IFNA1 • IL2

Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan-Meier curves of randomized trials. (PubMed, World J Gastrointest Pharmacol Ther) - "Our study compared the efficacy of the main first-line treatments recommended for unresectable HCC. While we were able to rank the magnitude of efficacy across these treatments, the intrinsic limitations of our methods (primarily the reconstruction of IPD and the indirect nature of the treatment comparisons) should be borne in mind."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis. (PubMed, J Gastrointest Oncol) - "For OS, TACE + anlotinib + sintilimab (TACE + Anl + Sin), TACE + donafenib + toripalimab (TACE + Don + Tor), TACE + lenvatinib + tislelizumab (TACE + Len + Tis), TACE + sorafenib + camrelizumab (TACE + Sor + Cam), and TACE + apatinib + camrelizumab (TACE + Apa + Cam) were all significantly superior to TACE alone...For PFS, compared with TACE alone, TACE + Anl + Sin, TACE + Don + Tor, TACE + lenvatinib + pembrolizumab (TACE + Len + Pem), TACE + Len + Tis, and TACE + Apa + Cam significantly prolonged PFS...For DCR, TACE + Len + Tis showed the best performance, while TACE + atezolizumab + bevacizumab (TACE + Ate + Bev), TACE + Anl + Sin, and TACE + Apa + Cam also demonstrated relatively high DCR. Compared with TACE alone, TACE combined with MTAs and ICIs can significantly improve outcomes in patients with uHCC. TACE + Anl + Sin, TACE + Len + Tis, and TACE + Apa + Cam may be promising treatment options, although more prospective studies are needed for further validation."

Checkpoint inhibition • Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Exceptional 106-month survival in multiply relapsed small cell lung cancer after sequential anlotinib and short-course sintilimab: a case report. (PubMed, Front Oncol) - "She achieved a partial response after concurrent chemoradiotherapy but developed recurrence in November 2018 and subsequently progressed after irinotecan-based and pemetrexed-based chemotherapy. However, because anlotinib had demonstrated activity before immunotherapy and was continued after sintilimab discontinuation, the relative contribution of each treatment cannot be determined. Further prospective studies with biomarker analyses are warranted."

IO biomarker • Journal • Endocrine Disorders • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor